These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 24550227)

  • 1. Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness.
    Messina M; Del Giudice I; Khiabanian H; Rossi D; Chiaretti S; Rasi S; Spina V; Holmes AB; Marinelli M; Fabbri G; Piciocchi A; Mauro FR; Guarini A; Gaidano G; Dalla-Favera R; Pasqualucci L; Rabadan R; Foà R
    Blood; 2014 Apr; 123(15):2378-88. PubMed ID: 24550227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications.
    Pérez-Carretero C; Hernández-Sánchez M; González T; Quijada-Álamo M; Martín-Izquierdo M; Hernández-Sánchez JM; Vidal MJ; de Coca AG; Aguilar C; Vargas-Pabón M; Alonso S; Sierra M; Rubio-Martínez A; Dávila J; Díaz-Valdés JR; Queizán JA; Hernández-Rivas JÁ; Benito R; Rodríguez-Vicente AE; Hernández-Rivas JM
    Int J Cancer; 2020 Nov; 147(10):2780-2792. PubMed ID: 32720348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.
    Ljungström V; Cortese D; Young E; Pandzic T; Mansouri L; Plevova K; Ntoufa S; Baliakas P; Clifford R; Sutton LA; Blakemore SJ; Stavroyianni N; Agathangelidis A; Rossi D; Höglund M; Kotaskova J; Juliusson G; Belessi C; Chiorazzi N; Panagiotidis P; Langerak AW; Smedby KE; Oscier D; Gaidano G; Schuh A; Davi F; Pott C; Strefford JC; Trentin L; Pospisilova S; Ghia P; Stamatopoulos K; Sjöblom T; Rosenquist R
    Blood; 2016 Feb; 127(8):1007-16. PubMed ID: 26675346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.
    Rossi D; Fangazio M; Rasi S; Vaisitti T; Monti S; Cresta S; Chiaretti S; Del Giudice I; Fabbri G; Bruscaggin A; Spina V; Deambrogi C; Marinelli M; Famà R; Greco M; Daniele G; Forconi F; Gattei V; Bertoni F; Deaglio S; Pasqualucci L; Guarini A; Dalla-Favera R; Foà R; Gaidano G
    Blood; 2012 Mar; 119(12):2854-62. PubMed ID: 22308293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene mutations in chronic lymphocytic leukemia.
    Amin NA; Malek SN
    Semin Oncol; 2016 Apr; 43(2):215-21. PubMed ID: 27040699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
    Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
    Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation.
    Fabbri G; Rasi S; Rossi D; Trifonov V; Khiabanian H; Ma J; Grunn A; Fangazio M; Capello D; Monti S; Cresta S; Gargiulo E; Forconi F; Guarini A; Arcaini L; Paulli M; Laurenti L; Larocca LM; Marasca R; Gattei V; Oscier D; Bertoni F; Mullighan CG; Foá R; Pasqualucci L; Rabadan R; Dalla-Favera R; Gaidano G
    J Exp Med; 2011 Jul; 208(7):1389-401. PubMed ID: 21670202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
    Nadeu F; Delgado J; Royo C; Baumann T; Stankovic T; Pinyol M; Jares P; Navarro A; Martín-García D; Beà S; Salaverria I; Oldreive C; Aymerich M; Suárez-Cisneros H; Rozman M; Villamor N; Colomer D; López-Guillermo A; González M; Alcoceba M; Terol MJ; Colado E; Puente XS; López-Otín C; Enjuanes A; Campo E
    Blood; 2016 Apr; 127(17):2122-30. PubMed ID: 26837699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.
    Rossi D; Bruscaggin A; Spina V; Rasi S; Khiabanian H; Messina M; Fangazio M; Vaisitti T; Monti S; Chiaretti S; Guarini A; Del Giudice I; Cerri M; Cresta S; Deambrogi C; Gargiulo E; Gattei V; Forconi F; Bertoni F; Deaglio S; Rabadan R; Pasqualucci L; Foà R; Dalla-Favera R; Gaidano G
    Blood; 2011 Dec; 118(26):6904-8. PubMed ID: 22039264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT.
    Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martina ZV; Saenko V; Bazyka DA
    Probl Radiac Med Radiobiol; 2018 Dec; 23():283-301. PubMed ID: 30582853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of IgA- and/or IgG-switched chronic lymphocytic leukemia B cells.
    Matolcsy A; Casali P; Nádor RG; Liu YF; Knowles DM
    Blood; 1997 Mar; 89(5):1732-9. PubMed ID: 9057657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations.
    Rigolin GM; Saccenti E; Bassi C; Lupini L; Quaglia FM; Cavallari M; Martinelli S; Formigaro L; Lista E; Bardi MA; Volta E; Tammiso E; Melandri A; Urso A; Cavazzini F; Negrini M; Cuneo A
    J Hematol Oncol; 2016 Sep; 9(1):88. PubMed ID: 27633522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
    Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
    Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
    Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
    Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.
    Rossi D; Khiabanian H; Spina V; Ciardullo C; Bruscaggin A; Famà R; Rasi S; Monti S; Deambrogi C; De Paoli L; Wang J; Gattei V; Guarini A; Foà R; Rabadan R; Gaidano G
    Blood; 2014 Apr; 123(14):2139-47. PubMed ID: 24501221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia.
    Amin NA; Seymour E; Saiya-Cork K; Parkin B; Shedden K; Malek SN
    Clin Cancer Res; 2016 Sep; 22(17):4525-35. PubMed ID: 27060156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia.
    Moussay E; Palissot V; Vallar L; Poirel HA; Wenner T; El Khoury V; Aouali N; Van Moer K; Leners B; Bernardin F; Muller A; Cornillet-Lefebvre P; Delmer A; Duhem C; Ries F; van Dyck E; Berchem G
    Mol Cancer; 2010 May; 9():115. PubMed ID: 20487546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia.
    Pandzic T; Larsson J; He L; Kundu S; Ban K; Akhtar-Ali M; Hellström AR; Schuh A; Clifford R; Blakemore SJ; Strefford JC; Baumann T; Lopez-Guillermo A; Campo E; Ljungström V; Mansouri L; Rosenquist R; Sjöblom T; Hellström M
    Clin Cancer Res; 2016 Dec; 22(24):6217-6227. PubMed ID: 26957556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.
    Rossi D; Cerri M; Deambrogi C; Sozzi E; Cresta S; Rasi S; De Paoli L; Spina V; Gattei V; Capello D; Forconi F; Lauria F; Gaidano G
    Clin Cancer Res; 2009 Feb; 15(3):995-1004. PubMed ID: 19188171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NOTCH1 mutations in CLL associated with trisomy 12.
    Balatti V; Bottoni A; Palamarchuk A; Alder H; Rassenti LZ; Kipps TJ; Pekarsky Y; Croce CM
    Blood; 2012 Jan; 119(2):329-31. PubMed ID: 22086416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.